Feed
Read More
Gilead Sciences: renewed growth story after years of stagnation
Company shares Gilead Sciences $GILD have risen by 44 %indicating a significant turnaround after years of stagnation. This growth trend is supported by new opportunities in innovative drugs and potential entry into the obesity market.
Key growth drivers for $GILD
1. Innovative medicines
- Lenacapavir: A promising HIV...
Read more
Interesting company, however I was probably most intrigued by $NVO.